Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02550678
Other study ID # ASN-002-001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2015
Est. completion date November 2017

Study information

Verified date June 2018
Source Ascend Biopharmaceuticals Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study evaluates whether ASN-002 is safe and effective in the treatment of nodular basal cell carcinoma (nBCC) in patients aged 18 years or over.

The participants will receive weekly injections of ASN-002 alone or in combination with 5-FU for 3 weeks and undergo surgical excision of the tumor.


Description:

The primary purpose of this study is to determine whether ASN-002 alone or in combination with 5-FU is safe and effective in the treatment of nodular basal cell carcinoma (nBCC).

Patients aged 18 or over, who have been diagnosed with nodular Basal Cell Carcinoma (nBCC), may be eligible to join this study.

Study details:

ASN-002 is an immunotherapeutic product that is injected into the BCC spot to be treated. It is made from modified adenovirus serotype 5 (also called Ad5). Adenoviruses are common in nature worldwide and can cause mild colds and respiratory infections from which people usually recover without treatment. The Ad5 used in this study has been modified so that it cannot grow in the body or cause an infection. The modified Ad5 in this study will deliver artificially made genetic material into the cancerous and surrounding cells. This genetic material will produce human interferon which is normally produced by the body to stimulate the immune system. It is hoped that injected ASN-002 will cause the body's own cells to produce interferon and stimulate the immune system to attack the cancerous cells and reduce the size of or eliminate the nBCC. Participants will attend the study centre weekly for an injection of ASN-002 alone of in combination with 5-FU into the nBCC. The participants recruited will have 3 injections over 3 weeks, and then undergo surgical excision of the tumor.

Patient outcomes will then be assessed using a tumour sample collected during surgery and by the incidence of adverse events which occur throughout the study.

It is hoped that the findings of this trial will provide information on the safety and efficacy of using ASN-002 alone or in combination with 5-FU for nBCC, particularly for patients in whom the standard treatment of surgery is not possible or not recommended.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date November 2017
Est. primary completion date November 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Low risk nodular basal cell carcinoma

2. Biopsy of any other skin tumor

3. Willingness to have injection therapy followed by surgery

4. Written informed consent

Exclusion Criteria:

1. No or only minimal symptoms

2. Known or suspected metastatic disease.

3. Pregnant or Lactating females

4. Clinically active or uncontrolled skin disease

5. Immunocompromised or receiving immunomodulating agent

6. treatment with psoralen plus Ultraviolet A or Ultraviolet B light therapy within 6 months

7. Any serious or active medical or psychiatric illness

8. Recreational or therapeutic drug or alcohol use

9. Taking any investigational product within 1 month of first dose of ASN- 002.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ASN-002
ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
Drug:
5-FU
5-FU is chemotherapeutic agent used to treat various cancers.

Locations

Country Name City State
Australia Siller Medical T/A Central Brisbane Dermatology Brisbane Queensland
Australia Veracity Clinical Research Brisbane Queensland
Australia St George Dermatology and Skin Cancer Centre Kogarah New South Wales
Australia Sinclair Dermatology Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
Ascend Biopharmaceuticals Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidences of ASN-002 related Adverse Event in patients with previously untreated nBCC changes in vital signs, adverse events, serious adverse events, laboratory abnormalities and withdrawals from study. Local skin and injection site reactions will be assessed in detail scoring erythema, ulceration, pain and overall severity as none, mild, moderate or severe. Participants will be followed up for up to 6 months.
Secondary Microscopic clearance of the injected basal cell carcinoma. Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests in serial histological samples as determined by central pathology review. Microscopic examinations of sample collected at 17weeks after the first dose.
Secondary Clinical Changes in size of nBCC tumor over time after treatment with ASN-002 alone or in combination with 5-FU Change in nBCC lesion size will be assessed by investigator at baseline and then every 4 weeks until the surgical excision of BCC after ASN-002 therapy. Change in nBCC will be assessed for up to 6 months from the first treatment visit.
See also
  Status Clinical Trial Phase
Completed NCT00555633 - Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients N/A
Recruiting NCT03483441 - Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS Phase 1
Active, not recruiting NCT03467789 - Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma Phase 1
Recruiting NCT05463757 - Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Completed NCT02762084 - Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients Phase 2
Terminated NCT04308395 - Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) Phase 3
Withdrawn NCT03767439 - Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome Phase 2
Completed NCT04416516 - Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor Phase 2
Recruiting NCT06330350 - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation NCT06330324 - Reproductive Options in Inherited Skin Diseases
Terminated NCT02303041 - Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Phase 2
Completed NCT02100371 - Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome N/A
Completed NCT03703310 - Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) Phase 3
Completed NCT02157623 - Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome N/A
Completed NCT00957229 - To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) Phase 2
Completed NCT01556009 - Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas Phase 2